ASCO2016: TRANSGENE Announces Poster Presentation At ASCO Annual Meeting On The Phase 3 PHOCUS Clinical Trial With Pexa-Vec Oncolytic Immunotherapy

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:

Transgene (Paris:TNG) (Euronext Paris: TNG), a company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases, today announced that a poster on the ongoing Pexa-Vec Phase 3 trial in first line advanced HCC patients will be presented at the American Society of Clinical Oncology (ASCO) Meeting on June 4th, in Chicago, IL, USA.